Cancer Family
Adnexal Neoplasm
CI-CAN-00000005Explore in graph →
Non-malignant777 active trials5 approved drugs94 evidence items
- NCIt
- C212119
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000005Explore in graph →
Clinical trials
3,522 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00770536 | AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR | completed | Phase 1 | 103 | AmgenINDUSTRY | 3 | Sep 29, 2015 | clinicaltrials |
| NCT00791778 | Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer | completed | Phase 2 | 246 | BayerINDUSTRY | 14 | Sep 28, 2015 | clinicaltrials |
| NCT01419210 |
| Pilot Program to Personalize Care & Improve Quality of Life for Women With Ovarian Cancer |
| completed |
| N/A |
| 28 |
| H. Lee Moffitt Cancer Center and Research InstituteOTHER |
| 1 |
| Sep 24, 2015 |
| clinicaltrials |
| NCT00318370 | Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy | completed | Phase 2 | 58 | MorphotekINDUSTRY | 2 | Sep 9, 2015 | clinicaltrials |
| NCT00746694 | A Study to Determine the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Caelyx (Study P05020) | completed | — | 154 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2015 | clinicaltrials |
| NCT01121406 | BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer | completed | Phase 2 | 110 | Boehringer IngelheimINDUSTRY | 5 | Aug 13, 2015 | clinicaltrials |
| NCT00003636 | Chemotherapy Plus Surgery in Treating Patients With Stage III or Stage IV Ovarian, Peritoneal, or Fallopian Tube Cancer | completed | Phase 3 | 704 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 15 | Aug 5, 2015 | clinicaltrials |
| NCT01652794 | Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer | completed | Phase 1 | 12 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 4, 2015 | clinicaltrials |
| NCT00945139 | Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA) | completed | Phase 2 | 46 | New Mexico Cancer Research AllianceOTHER | 1 | Jul 31, 2015 | clinicaltrials |
| NCT00421889 | A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment | completed | Phase 1 / Phase 2 | 80 | Valerio TherapeuticsINDUSTRY | 3 | Jul 28, 2015 | clinicaltrials |
| NCT00072267 | UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | — | University Health Network, TorontoOTHER | 1 | Jul 23, 2015 | clinicaltrials |
| NCT01657747 | Whole-body Diffusion MRI for Staging, Response Prediction and Detecting Tumor Recurrence in Patients With Ovarian Cancer(S53580) | completed | N/A | 350 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Jul 2, 2015 | clinicaltrials |
| NCT00096993 | A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 131 | Genentech, Inc.INDUSTRY | 1 | Jun 10, 2015 | clinicaltrials |
| NCT01690598 | Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status | completed | Phase 1 / Phase 2 | 22 | Vejle HospitalOTHER | 1 | Jun 10, 2015 | clinicaltrials |
| NCT01709175 | Strength Training Study for Survivors of Breast and Gynecologic Cancer | completed | N/A | 20 | Nova Scotia Health AuthorityOTHER | 1 | Jun 8, 2015 | clinicaltrials |
| NCT00343044 | Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers | completed | Phase 2 | 40 | Benaroya Research InstituteOTHER | 1 | May 15, 2015 | clinicaltrials |
| NCT00072566 | Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | May 12, 2015 | clinicaltrials |
| NCT00060359 | Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | 32 | Gynecologic Oncology GroupNETWORK | 1 | May 8, 2015 | clinicaltrials |
| NCT01196741 | Saracatinib and Paclitaxel in Platinum-resistant Ovarian Cancer(SaPPrOC) | completed | Phase 2 / Phase 3 | 107 | University College, LondonOTHER | 1 | May 5, 2015 | clinicaltrials |
| NCT00006981 | Immunotoxin Therapy in Treating Patients With Advanced Cancer | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00039585 | Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00066651 | Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00267696 | Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer | completed | Phase 2 | 45 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 30, 2015 | clinicaltrials |
| NCT02016833 | Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity | completed | — | 15 | PX BiosolutionsINDUSTRY | 1 | Apr 30, 2015 | clinicaltrials |
| NCT00019136 | Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial Cancer | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00020150 | Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors | completed | Phase 1 | — | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2015 | clinicaltrials |
| NCT01810874 | STELLA Trial: Transperitoneal vs. Extraperitoneal Approach for Laparoscopic Staging of Endometrial/Ovarian Cancer(STELLA) | completed | N/A | 60 | Hospital Universitari Vall d'Hebron Research InstituteOTHER | 1 | Apr 29, 2015 | clinicaltrials |
| NCT00743431 | Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (Study P04085)(COMPLETED) | completed | — | 224 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 15, 2015 | clinicaltrials |
| NCT01242436 | Whole Body Diffusion MRI for Non-invasive Lesion Detection and Therapy Follow-up: Study With Patients With Ovarian Cancer and Peritoneal Metastasis | completed | N/A | 50 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Apr 10, 2015 | clinicaltrials |
| NCT00346385 | BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 97 | ImmunoGen, Inc.INDUSTRY | 2 | Mar 26, 2015 | clinicaltrials |
| NCT00127920 | Pilot Study of Taxol, Carboplatin, and Bevacizumab in Advanced Stage Ovarian Carcinoma Patients | completed | Phase 2 | 20 | Gynecologic Oncology AssociatesOTHER | 1 | Mar 10, 2015 | clinicaltrials |
| NCT00345540 | Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer | completed | Phase 2 | 15 | Cellectar Biosciences, Inc.INDUSTRY | 1 | Mar 10, 2015 | clinicaltrials |
| NCT01227928 | Efficacy and Safety of Pazopanib Monotherapy After First-line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Asian Women | completed | Phase 2 | 145 | GlaxoSmithKlineINDUSTRY | 4 | Mar 3, 2015 | clinicaltrials |
| NCT00090610 | Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer | completed | Phase 2 | 150 | Duke UniversityOTHER | 1 | Feb 25, 2015 | clinicaltrials |
| NCT01047891 | Efficacy and Safety Study of Sorafenib With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer(TRIAS 2009) | completed | Phase 2 | 174 | JSehouliOTHER | 1 | Feb 18, 2015 | clinicaltrials |
| NCT01196559 | Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer | completed | Phase 2 | 44 | The Catholic University of KoreaOTHER | 1 | Feb 18, 2015 | clinicaltrials |
| NCT01815528 | Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer | completed | Phase 2 | 2 | JSehouliOTHER | 1 | Feb 18, 2015 | clinicaltrials |
| NCT00388037 | Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Jan 27, 2015 | clinicaltrials |
| NCT00959582 | Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143) | completed | Phase 1 | 42 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 22, 2015 | clinicaltrials |
| NCT00415181 | Pharmacogenomics of Paclitaxel in Ovarian Cancer | completed | — | 93 | University of Southern DenmarkOTHER | 2 | Jan 13, 2015 | clinicaltrials |
| NCT00507741 | Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02) | completed | Phase 2 | 49 | EndocyteINDUSTRY | 0 | Jan 7, 2015 | clinicaltrials |
| NCT00722592 | Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04)(PRECEDENT) | completed | Phase 2 | 162 | EndocyteINDUSTRY | 0 | Jan 7, 2015 | clinicaltrials |
| NCT00352300 | Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer | completed | Phase 1 | 43 | Gynecologic Oncology GroupNETWORK | 1 | Dec 31, 2014 | clinicaltrials |
| NCT00814086 | Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer | completed | Phase 1 | 23 | Gynecologic Oncology GroupNETWORK | 1 | Dec 31, 2014 | clinicaltrials |
| NCT01294293 | TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | completed | Phase 1 | 20 | Gynecologic Oncology GroupNETWORK | 1 | Dec 25, 2014 | clinicaltrials |
| NCT01131234 | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00390611 | Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer | completed | Phase 2 | 85 | SCRI Development Innovations, LLCOTHER | 1 | Dec 22, 2014 | clinicaltrials |
| NCT02004093 | A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer | completed | Phase 2 | 149 | Hoffmann-La RocheINDUSTRY | 9 | Dec 4, 2014 | clinicaltrials |
| NCT02298855 | Individualised Versus Conventional Medical Follow-up for Women After Primary Treatment for Ovarian Cancer. | completed | N/A | 113 | University College, LondonOTHER | 1 | Nov 24, 2014 | clinicaltrials |
Data updated 24 days agoSource updated Sep 29, 2015source: clinicaltrials